TXG

10x Genomics, Inc. Class A Common Stock

TXG
Closed
$10.41
Closed
-$0.17(-1.56%)

At close

About

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,306 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Country

US

CEO

Mr. Serge Saxonov

IPO date

2019

Employees

1,306

ISIN

US88025U1097

Key stats

Open

$11.61

Volume

32.93M

Market cap

$1.32B

Prev. close

$10.58

Impl / hst vl

-

Open interest

$0.00

$0.00

Day’s Range

$0.00

$6.78

52W Range

$24.76

Valuation

50
Valuation score
Fairly Valued
P/E
-
P/S
1.73
P/B
1.52
Current ratio
5.37
Debt / Equity
-0.53
ROE
-21.93%
Gross margin
68.08%
Income growth
-29.92%
FCF growth
-442.96

Analysts estimates

Consensus rating
Hold

The average rating from top 23 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$12.93
The top 17 analysts forecasts that 12-month price may increase by 24.23%, with a low of $6.57 and a high of $18.90
$6.57
Low
$12.93
Avg
$18.90
High
Current price

Earnings

Q1 ‘25 revenue
$154.88M
Q1 ‘25 net income
-$34.36M
Revenue
Net income
Previous EPS
-
Estimate EPS
-$0.29
Actual EPS
Estimate EPS